Antisense and RNAi Therapeutics Market

Report Highlights

The scope of this report is broad and covers different Technologies of Antisense and RNAi Therapeutics, along with the applications for Antisense and RNAi Therapeutics and Antisense and RNAi Therapeutics. The market is broken down by technologies of antisense and RNAI therapeutics, applications, and regional markets. Revenue forecasts from 2019 to 2025 are given for each major Technology of Antisense and RNAi Therapeutics, application, and regional market, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional Antisense and RNAi Therapeutics markets; it explains the major market drivers of the global Antisense and RNAi Therapeutics industry, current trends within the industry, major applications, and the regional dynamics of the global Antisense and RNAi Therapeutics market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global Antisense and RNAi Therapeutics industry.

Report Includes

• 62 tables
• An up-to-date analysis of the global Antisense and RNAi Therapeutics market.
• Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
• Estimation of market size and revenue forecast for global Antisense and RNAi Therapeutics market, and corresponding market share analysis by Technology, application, route of administration and region for each market segment.
• Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Antisense and RNAi Therapeutics, identification of the companies that are best positioned to meet this demand.
• In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
• Identification of new products and products still in the development and their probability of successful commercial launch within the next five years
• Impact of COVID-19 on the Antisense and RNAi Therapeutics market as compared to overall global economy.
• Insight into the growth development strategies of major Antisense and RNAi Therapeutics manufacturers and their key competitive landscape
• Descriptive company profiles of the leading market participants, including Isis Pharmaceuticals, Antisense Therapeutics, Tekmira Pharmaceuticals, Sanofi, Allergan, Ascletis and AstraZeneca.

Summary.

Antisense and RNAi therapeutics make specific and highly effectual gene silencing possible. Antisense technology provides a chance to influence the expression of gene and therefore, it is regarded as an efficient therapy for targeting ribonucleic acids (RNA). It is mostly used for cardiovascular diseases, oncology, renal diseases, neurodegenerative disorders, respiratory disorders, genetic disorders, infectious diseases, and others.

The Antisense and RNAi therapeutics market based on technology is divided into RNA Interference, siRNA, miRNA and Antisense RNA. In 2020, The Antisense RNA segment is projected to lead the market.